120 related articles for article (PubMed ID: 38151388)
1. Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.
Phillips T; Lugtenburg P; Kalsekar A; Mutebi A; Wang A; Blaedel J; Kosa K; Martin S; Sacchi M; Kilavuz N; Thieblemont C
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e78-e87.e2. PubMed ID: 38151388
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
[TBL] [Abstract][Full Text] [Related]
4. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
Herdman M; Kerr C; Pavesi M; Garside J; Lloyd A; Cubi-Molla P; Devlin N
J Patient Rep Outcomes; 2020 Mar; 4(1):22. PubMed ID: 32219576
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Spira A; Zhou X; Chen L; Gnanasakthy A; Wang L; Ungar D; Curiel R; Liao L; Radford J; Kahl B
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):158-168. PubMed ID: 34690090
[TBL] [Abstract][Full Text] [Related]
6. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study.
Gordon LI; Liu FF; Braverman J; Hoda D; Ghosh N; Hamadani M; Hildebrandt GC; Peng L; Guo S; Shi L; Sehgal A
Haematologica; 2024 Mar; 109(3):857-866. PubMed ID: 37646670
[TBL] [Abstract][Full Text] [Related]
7. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C; Phillips T; Ghesquieres H; Cheah CY; Clausen MR; Cunningham D; Do YR; Feldman T; Gasiorowski R; Jurczak W; Kim TM; Lewis DJ; van der Poel M; Poon ML; Cota Stirner M; Kilavuz N; Chiu C; Chen M; Sacchi M; Elliott B; Ahmadi T; Hutchings M; Lugtenburg PJ
J Clin Oncol; 2023 Apr; 41(12):2238-2247. PubMed ID: 36548927
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Ann Hematol; 2017 Feb; 96(2):253-259. PubMed ID: 27900446
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
10. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M; Mous R; Clausen MR; Johnson P; Linton KM; Chamuleau MED; Lewis DJ; Sureda Balari A; Cunningham D; Oliveri RS; Elliott B; DeMarco D; Azaryan A; Chiu C; Li T; Chen KM; Ahmadi T; Lugtenburg PJ
Lancet; 2021 Sep; 398(10306):1157-1169. PubMed ID: 34508654
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological characteristics and clinical outcomes of Epcoritamab (recombinant) (Epkinly
Takaura K; Ando H; Ganoza ER
Nihon Yakurigaku Zasshi; 2024; 159(1):61-68. PubMed ID: 38171842
[TBL] [Abstract][Full Text] [Related]
12. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Patrick DL; Powers A; Jun MP; Kim Y; Garcia J; Dehner C; Maloney DG
Blood Adv; 2021 Apr; 5(8):2245-2255. PubMed ID: 33904895
[TBL] [Abstract][Full Text] [Related]
13. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.
Hess G; Rule S; Jurczak W; Jerkeman M; Santucci Silva R; Rusconi C; Caballero D; Joao C; Witzens-Harig M; Bence-Bruckler I; Cho SG; Zhou W; Goldberg JD; Trambitas C; Enny C; Vermeulen J; Traina S; Chiou CF; Diels J; Dreyling M
Leuk Lymphoma; 2017 Dec; 58(12):2824-2832. PubMed ID: 28556689
[TBL] [Abstract][Full Text] [Related]
16. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment.
van der Horst HJ; de Jonge AV; Hiemstra IH; Gelderloos AT; Berry DRAI; Hijmering NJ; van Essen HF; de Jong D; Chamuleau MED; Zweegman S; Breij ECW; Roemer MGM; Mutis T
Blood Cancer J; 2021 Feb; 11(2):38. PubMed ID: 33602901
[TBL] [Abstract][Full Text] [Related]
17. Epcoritamab: First Approval.
Frampton JE
Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer.
Criscitiello C; Spurden D; Piercy J; Rider A; Williams R; Mitra D; Wild R; Corsaro M; Kurosky SK; Law EH
Clin Ther; 2021 Jul; 43(7):1228-1244.e4. PubMed ID: 34256965
[TBL] [Abstract][Full Text] [Related]
19. Validity and reliability of EQ-5D-3L for breast cancer patients in Korea.
Kim SH; Jo MW; Lee JW; Lee HJ; Kim JK
Health Qual Life Outcomes; 2015 Dec; 13():203. PubMed ID: 26694964
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy M; Chavez JC; Avivi I; Larouche JF; Wannesson L; Cwynarski K; Osman K; Davison K; Rudzki JD; Dahiya S; Dorritie K; Jaglowski S; Radford J; Morschhauser F; Cunningham D; Martin Garcia-Sancho A; Tzachanis D; Ulrickson ML; Karmali R; Kekre N; Thieblemont C; Enblad G; Dreger P; Malladi R; Joshi N; Wang WJ; Solem CT; Snider JT; Cheng P; To C; Kersten MJ
Blood; 2022 Nov; 140(21):2248-2260. PubMed ID: 35839452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
